Omnia Education: Exclusively Women’s Health Education - Omnia Education

Exclusively Women’s Health Education

Exclusively Women’s Health Education

Enhance your practice with CME
and tools that focus on diseases and
conditions impacting the female patient.

Popular

From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
MinuteCE®
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 program credits
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
0.50 program credits
- Erica L. Mayer, MD, MPH
0.50 program credits
CME/CE In-Person Event
22nd Annual Women’s Health Annual Visit (WHAV)
December 04, 2026
New York, New York
7.00 credits
Escalate With Intention: Stepwise, Target-Anchored Moves
Escalate With Intention: Stepwise, Target-Anchored Moves
MinuteCE®
Escalate With Intention: Stepwise, Target-Anchored Moves
Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
Shared Goals, Shared Gains: Align With Patient Preferences
Shared Goals, Shared Gains: Align With Patient Preferences
MinuteCE®
Shared Goals, Shared Gains: Align With Patient Preferences
Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
Minimal By Design: Define MSE Endpoints
Minimal By Design: Define MSE Endpoints
MinuteCE®
Minimal By Design: Define MSE Endpoints
Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
FcRn: Same Class, Different Paths—Spot Agent Differentiators
FcRn: Same Class, Different Paths—Spot Agent Differentiators
MinuteCE®
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit

CME/CE

ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
MinuteCE®
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 credits 4 episodes
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 credits 4 episodes
Turning Flares Into Function: Flag Uncontrolled Disease
Turning Flares Into Function: Flag Uncontrolled Disease
MinuteCE®
Turning Flares Into Function: Flag Uncontrolled Disease
Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
The IgG Clock: Redose Using IgG Kinetics
The IgG Clock: Redose Using IgG Kinetics
MinuteCE®
The IgG Clock: Redose Using IgG Kinetics
Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
The 2-Point Signal: Apply ≥2-Point Rule
The 2-Point Signal: Apply ≥2-Point Rule
MinuteCE®
The 2-Point Signal: Apply ≥2-Point Rule
Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
The Alloimmune Disorders of Pregnancy
The Alloimmune Disorders of Pregnancy
MinuteCE®
The Alloimmune Disorders of Pregnancy
Karin J. Blakemore, MD; Emilie L. Vander Haar
1.00 program credit
- Karin J. Blakemore, MD
- Emilie L. Vander Haar
1.00 program credit
Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First”
Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First”
MinuteCE®
Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First”
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP; James A. Simon, MD, CCD, NCMP, IF, FACOG
1.75 program credits
- Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
- James A. Simon, MD, CCD, NCMP, IF, FACOG
1.75 program credits
The Integral Role of GnRH Antagonists in the Management of Endometriosis
The Integral Role of GnRH Antagonists in the Management of Endometriosis
MinuteCE®
The Integral Role of GnRH Antagonists in the Management of Endometriosis
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP; Sawsan As-Sanie, MD
1.75 program credits
- Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
- Sawsan As-Sanie, MD
- James A. Simon, MD, CCD, NCMP, IF, FACOG
1.75 program credits

Clinical Practice

Target Locked in gMG: Why T2T Matters
Target Locked in gMG: Why T2T Matters
MinuteCE®
Target Locked in gMG: Why T2T Matters
Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
When to Begin FcRn: Initiation Criteria, Key Evidence
When to Begin FcRn: Initiation Criteria, Key Evidence
MinuteCE®
When to Begin FcRn: Initiation Criteria, Key Evidence
Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN
1.00 program credit
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 program credit
Capturing the Impact of Endometriosis on Health-Related QoL: The Role of Patient Questionnaires
Capturing the Impact of Endometriosis on Health-Related QoL: The Role of Patient Questionnaires
MinuteCE®
Capturing the Impact of Endometriosis on Health-Related QoL: The Role of Patient Questionnaires
Lee P. Shulman, MD, FACMG, FACOG; Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
1.75 program credits
- Lee P. Shulman, MD, FACMG, FACOG
- Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
1.75 program credits
Clinical Considerations for the Diagnosis of Endometriosis
Clinical Considerations for the Diagnosis of Endometriosis
MinuteCE®
Clinical Considerations for the Diagnosis of Endometriosis
Linda Bradley, MD; James A. Simon, MD, CCD, NCMP, IF, FACOG
1.75 program credits
- Linda Bradley, MD
- James A. Simon, MD, CCD, NCMP, IF, FACOG
1.75 program credits
Cut to the Chase: Why Not Treat Endometriosis With GnRH Antagonists First?
Cut to the Chase: Why Not Treat Endometriosis With GnRH Antagonists First?
MinuteCE®
Cut to the Chase: Why Not Treat Endometriosis With GnRH Antagonists First?
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP; Sawsan As-Sanie, MD
1.75 program credits
- Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
- Sawsan As-Sanie, MD
- James A. Simon, MD, CCD, NCMP, IF, FACOG
1.75 program credits
It’s Not Just Black and White: Seeing the Full Spectrum of Endometriosis Cases
It’s Not Just Black and White: Seeing the Full Spectrum of Endometriosis Cases
MinuteCE®
It’s Not Just Black and White: Seeing the Full Spectrum of Endometriosis Cases
Linda Bradley, MD; Melissa Simon, MD
1.75 program credits
- Linda Bradley, MD
- Melissa Simon, MD
- Casey Joe Hinds
1.75 program credits
Pre- and Postoperative Use of GnRH Antagonists
Pre- and Postoperative Use of GnRH Antagonists
MinuteCE®
Pre- and Postoperative Use of GnRH Antagonists
Lee P. Shulman, MD, FACMG, FACOG; Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
1.75 program credits
- Lee P. Shulman, MD, FACMG, FACOG
- Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
1.75 program credits
MinuteCE®
Changing the Mindset in the Management of Endometriosis: Hitting the Pause Button on Surgical Procedures and Expanding the Role of GnRH Antagonists
Lee P. Shulman, MD, FACMG, FACOG; Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
1.75 credits 10 episodes
- Lee P. Shulman, MD, FACMG, FACOG
- Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
- Sawsan As-Sanie, MD
- Linda Bradley, MD
- James A. Simon, MD, CCD, NCMP, IF, FACOG
- Melissa Simon, MD
- Samantha Denäe
- Casey Joe Hinds
1.75 credits 10 episodes

Programs

MinuteCE®
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN
1.00 credit 10 episodes
- Christyn Edmundson, MD
- Gil I. Wolfe MD, FAAN
1.00 credit 10 episodes
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
MinuteCE®
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Christyn Edmundson, MD
1.00 program credit
- Christyn Edmundson, MD
1.00 program credit
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
MinuteCE®
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
Lee P. Shulman, MD, FACMG, FACOG; Linda Bradley, MD
1.75 program credits
- Lee P. Shulman, MD, FACMG, FACOG
- Linda Bradley, MD
- Samantha Denäe
1.75 program credits
Can We Talk? Optimizing Patient Buy-In to the Management of Endometriosis
Can We Talk? Optimizing Patient Buy-In to the Management of Endometriosis
MinuteCE®
Can We Talk? Optimizing Patient Buy-In to the Management of Endometriosis
Lee P. Shulman, MD, FACMG, FACOG; Linda Bradley, MD
1.75 program credits
- Lee P. Shulman, MD, FACMG, FACOG
- Linda Bradley, MD
1.75 program credits
Parallels Between Kidney Transplantation and Maternal Anti-Fetal Rejection
Parallels Between Kidney Transplantation and Maternal Anti-Fetal Rejection
CME/CE
Parallels Between Kidney Transplantation and Maternal Anti-Fetal Rejection
Lee P. Shulman, MD, FACMG, FACOG; Alexandra Benachi, MD, PhD
- Lee P. Shulman, MD, FACMG, FACOG
- Alexandra Benachi, MD, PhD
- Julien Zuber, MD, PhD
Alloimmune Thrombocytopenia in the Fetus and Newborn
Alloimmune Thrombocytopenia in the Fetus and Newborn
CME/CE
Alloimmune Thrombocytopenia in the Fetus and Newborn
Lee P. Shulman, MD, FACMG, FACOG; James B. Bussel, MD
0.25 credits
- Lee P. Shulman, MD, FACMG, FACOG
- James B. Bussel, MD
0.25 credits
Introduction to Alloimmunization During Pregnancy
Introduction to Alloimmunization During Pregnancy
The Alloimmune Disorders of Pregnancy
Introduction to Alloimmunization During Pregnancy
Roberto Romero, MD, DMedSci
- Roberto Romero, MD, DMedSci
Red Blood Cell Alloimmunization, Pathophysiology, Diagnosis, Treatment, and Prevention
Red Blood Cell Alloimmunization, Pathophysiology, Diagnosis, Treatment, and Prevention
CME/CE
Red Blood Cell Alloimmunization, Pathophysiology, Diagnosis, Treatment, and Prevention
Lee P. Shulman, MD, FACMG, FACOG; Kenneth J. Moise Jr., MD
- Lee P. Shulman, MD, FACMG, FACOG
- Kenneth J. Moise Jr., MD